Vaccine production, distribution, access, and uptake

The Lancet

Volumn 378, Issue 9789, 2011, Pages 428-438

  Smith, Jon ^a   Lipsitch, Marc ^b   Almond, Jeffrey W ^a  

^a SANOFI PASTEUR   (France)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; BCG VACCINE; DIPHTHERIA VACCINE; EXCIPIENT; HEMAGGLUTININ; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; ROTAVIRUS VACCINE; SABIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

BUDGET; CELL CULTURE; CLINICAL TRIAL; DRUG ANTIGENICITY; DRUG APPROVAL; DRUG CONCENTRATION; DRUG COST; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG LABELING; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG POTENCY; DRUG QUALITY; DRUG RESEARCH; DRUG SCREENING; DRUG STABILITY; DRUG STERILITY; DRUG UTILIZATION; ECONOMIC ASPECT; EPIDEMIC; EUROPE; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INSECT CELL; LICENSING; MASS IMMUNIZATION; MEDICAL TECHNOLOGY; MICROBIOLOGICAL EXAMINATION; NEUROSPORA CRASSA; NONHUMAN; NORTHERN HEMISPHERE; OSMOLALITY; PH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DESIGN; PROTEIN EXPRESSION; PURCHASING; QUALITY CONTROL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEASONAL VARIATION; SHELF LIFE; SYRINGE; TOBACCO; UNITED STATES; VACCINE ACCESS; VACCINE DISTRIBUTION; VACCINE PRODUCTION; VACCINE SUPPLY; VACCINE UPTAKE; VIROGENESIS; WORLD HEALTH ORGANIZATION;

EID: 79960958090     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60478-9     Document Type: Review

References (88)

1. Levine OS, Bloom DE, Cherian T, et al. The future of immunisation policy, implementation, and financing. Lancet 2011; published online June 9. DOI:10.1016/S0140-6736(11)60406-6.
2. WHO. UN prequalified vaccines: WHO list of vaccines for purchase by UN agencies (May, 2006). https://apps.who.int/vaccines-access/quality/un- prequalified/prequalvaccinesproducers.html (accessed May 14, 2011).
3. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 3949.
4. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 4377.
5. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 3384.
6. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 3132.
7. The European Directorate for the Quality of Medicines. European Pharmacopoeia, 7th edn. Ogdensburg: Renouf Books, 2011: 443.
8. The European Directorate for the Quality of Medicines. European Pharmacopoeia, 7th edn. Ogdensburg: Renouf Books, 2011: 161.
9. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 1993.
10. The European Directorate for the Quality of Medicines. European Pharmacopoeia, 7th edn. Ogdensburg: Renouf Books, 2011: 1056.
11. The European Directorate for the Quality of Medicines. European Pharmacopoeia, 7th edn. Ogdensburg: Renouf Books, 2011: 1219.
12. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 3570.
13. United States Pharmacopeia National Formulary 2011: USP 34 NF 29. Maryland: United States Pharmacopeia, 2011: 4187.
14. Pan American Health Organization. Poliomyelitis eradication: field guide. Washington, DC: Pan American Health Organization, 2006. http://www.paho.org/ english/ad/fch/im/fieldguide-polio.pdf (accessed May 18, 2011).
15. Modlin JF. The bumpy road to polio eradication. N Engl J Med 2010; 362: 2346-49.
16. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362-66.
17. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159: 907-13. (Pubitemid 41423328)
18. McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 2006; 98: 433.
19. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353: 1555-63. (Pubitemid 41434634)
20. WHO. A system for the prequalification of vaccines for UN supply. http://www.who.int/immunization-standards/vaccine-quality/pq-system/en/index. html (accessed May 13, 2011).
21. European Council. Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. http://ec.europa.eu/health/files/eudralex/vol-1/ reg-2004-726-cons/reg-2004-726-cons-en.pdf (accessed May 18, 2011).
22. GAVI Alliance. Eligible countries. http://www.gavialliance.org/support/ who/index.php (accessed May 15, 2011).
23. UNICEF. Supplies and logistics: GAVI. http://www.unicef.org/supply/index- gavi.html (accessed May 18, 2011).
24. UK Health Protection Agency. Routine childhood immunisation schedule. http://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListDate/Page/ 1204031508623 (accessed May 14, 2011).
25. US Centers for Disease Control and Prevention. Immunization schedules. http://www.cdc.gov/vaccines/recs/schedules (accessed May 14, 2011).
26. WHO. WHO African region. Routine EPI activities. http://www.who.int/ countries/eth/areas/immunization/routine/en/index3.html (accessed May 14, 2011).
27. Nielsen A, Larsen SO. Epidemiology of pertussis in Denmark: the impact of herd immunity. Int J Epidemiol 1994; 23: 1300-08.
28. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009; 361: 271-78.
29. GAVI Alliance. Facts and figures. http://www.gavialliance.org/media- centre/facts/index.php (accessed May 15, 2011).
30. GAVI Alliance. Key indicators: measuring the Alliance's progress against its four strategic goals. http://www.gavialliance.org/performance/global- results/GAVI-Alliance-Results-2008-Vaccines.php (accessed Oct 1, 2010).
31. Wolfson LJ, Gasse F, Lee-Martin SP, et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 2008; 86: 27-39.
32. GAVI Alliance. Investing in immunisation through the GAVI Alliance: the evidence base. http://www.gavialliance.org/resources/GAVI-Evidence-Base-2010.pdf (accessed May 18, 2011).
33. GAVI Alliance. Innovative financing. http://www.gavialliance.org/vision/ in-financing/index.php (accessed May 18, 2011).
34. GAVI Alliance. What you can apply for. http://www.gavialliance.org/ support/what/index.php (accessed May 15, 2011).
35. WHO. Cholera fact sheet. http://www.who.int/mediacentre/factsheets/fs107/ en (accessed May 13, 2011).
36. Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile - a new humanitarian and diplomatic resource. N Engl J Med 2010; 363: 2279-82.
37. Ivers LC, Farmer P, Almazor CP, Léandre F. Five complementary interventions to slow cholera: Haiti. Lancet 2010; 376: 2048-51.
38. WHO. Global alert and response. Confirmed human cases of avian influenza A(H5N1). http://www.who.int/csr/disease/avian-influenza/country/en (accessed May 14, 2011).
39. WHO. Global alert and response. Pandemic (H1N1) 2009. http://www.who.int/csr/disease/swineflu/en (accessed May 14, 2011).
40. Moxon ER, Siegrist C-A. The next decade of vaccines: societal and scientific challenges. Lancet 2011; published online June 9. DOI:10.1016/S0140-6736(11)60407-8.
41. WHO. WHO global influenza surveillance network. http://www.who.int/csr/ disease/influenza/surveillance/en/index.html (accessed May 7, 2011).
42. Minor PD, Engelhardt OG, Wood JM, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27: 2907-13.
43. The European Agency for the Evaluation of Medicinal Products. Harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003945.pdf (accessed May 7, 2011).
44. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009; 8: 679-88.
45. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8: 607-18.
46. Koudstaal W, Hartgroves L, Havenga M, et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 2009; 27: 2588-93.
47. Meghrous J, Mahmoud W, Jacob D, Chubet R, Cox M, Kamen AA. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. Vaccine 2009; 28: 309-16.
48. Novavax. Research and development programs. http://www.novavax.com/go. cfm?do=Page.View&pid=20#flu (accessedMay 15, 2011).
49. G-Con. Texas-based consortium announces project GreenVax: a groundbreaking vaccine manufacturing research program. Feb 24, 2010. http://gconbio.com/docs/GCON-GreenVax-Release02242010.pdf (accessed May 15, 2011).
50. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010; 8: 607-19.
51. Allgaier S, Taylor RD, Brudnaya Y, Jacobson DJ, Cambareri E, Stuart WD. Vaccine production in Neurospora crassa. Biologicals 2009; 37: 128-32.
52. European Medicines Agency. Annex I. Summary of product characteristics: influenza vaccine H1N1v. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000710/WC500023749.pdf (accessed May 16, 2011).
53. European Medicines Agency. Annex I. Summary of product characteristics: influenza vaccine (H1N1)v. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000832/WC500038121.pdf (accessed May 16, 2011).
54. European Medicines Agency. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). EMEA/CPMP/VEG/4717/2003- Rev.1. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003869.pdf (accessed May 16, 2011).
55. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005; 26: 4-29. (Pubitemid 40632275)
56. Fidler DP. Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. PLoS Med 2010; 7: e1000247.
57. WHO. Update on A(H1N1) pandemic and seasonal vaccine availability (July 7, 2009). http://www.who.int/immunization/sage/3.MPK-SAGE-7-July.pdf (accessed May 7, 2011).
58. Wallinga J, van Boven M, Lipsitch M. Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci USA 2010; 107: 923-28.
59. Dushoff J, Plotkin JB, Viboud C, et al. Vaccinating to protect a vulnerable subpopulation. PLoS Med 2007; 4: e174.
60. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-66. (Pubitemid 47444564)
61. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
62. Fraser C, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-61.
63. Lessler J, Santos TD, Aguilera X, Brookmeyer R, Cummings DA. H1N1pdm in the Americas. Epidemics 2010; 2: 132-38.
64. Nishiura H, Castillo-Chavez C, Safan M, Chowell G. Transmission potential of the new influenza A (H1N1) virus and its age-specificity in Japan. Euro Surveill 2009; 14: 19227.
65. White LF, Wallinga J, Finelli L, et al. Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA. Influenza Other Respir Vir 2009; 3: 267-76.
66. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in southeast Asia. Nature 2005; 437: 209-14. (Pubitemid 41294478)
67. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004; 432: 904-06. (Pubitemid 40037151)
68. Andreasen V, Viboud C, Simonsen L. Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. J Infect Dis 2008; 197: 270-78. (Pubitemid 351263447)
69. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic.Nature 2006; 442: 448-52. (Pubitemid 44264793)
70. Fraser C. Estimating individual and household reproduction numbers in an emerging epidemic. PLoS One 2007; 2: e758.
71. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006; 103: 5935-40.
72. Goldstein E, Paur K, Fraser C, Kenah E, Wallinga J, Lipsitch M. Reproductive numbers, epidemic spread and control in a community of households. Math Biosci 2009; 221: 11-25.
73. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5: e74.
74. Goldstein E, Apolloni A, Lewis B, et al. Distribution of vaccine/antivirals and the 'least spread line' in a stratified population. J R Soc Interface 2010; 7: 755-64.
75. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005; 161: 303-06. (Pubitemid 40256201)
76. Loeb M, Russell ML, Moss L, et al. Eff ect of influenza vaccination ofchildren on infection rates in Hutterite communities: a randomizedtrial. JAMA 2010; 303: 943-50.
77. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ,Fukuda K. Pandemic versus epidemic influenza mortality: apattern of changing age distribution. J Infect Dis 1998; 178: 53-60. (Pubitemid 28328076)
78. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four diff erent methods. Influenza Other Respir Vir 2009; 3: 37-49.
79. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16: 1389-91.
80. Cassone A, Rappuoli R. Universal vaccines: shifting to one for many. MBio 2010; 1: e00042-10.
81. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999; 5: 336-45. (Pubitemid 29289447)
82. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; published online April 13. DOI:10.1016/S0140-6736(10)62225-8.
83. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995; 13: 1399-402.
84. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 2011; 108: 757-61.
85. Steel J, Lowen AC, Wang T, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1: e00018-10.
86. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-73.
87. Wang TT, Tan GS, Hai R, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010; 107: 18979-84.
88. Almond JW. Vaccine renaissance. Nat Rev Microbiol 2007; 5: 478-81. (Pubitemid 46925374)